

Rury R Holman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2996959/publications.pdf>

Version: 2024-02-01

147
papers

29,661
citations

41344

49
h-index

8396

147
g-index

151
all docs

151
docs citations

151
times ranked

20300
citing authors

#	ARTICLE	IF	CITATIONS
1	10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2008, 359, 1577-1589.	27.0	6,543
2	Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy. <i>Diabetes Care</i> , 2009, 32, 193-203.	8.6	2,988
3	Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy. <i>New England Journal of Medicine</i> , 2006, 355, 2427-2443.	27.0	2,714
4	Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2015, 373, 232-242.	27.0	2,188
5	Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017, 377, 1228-1239.	27.0	1,455
6	Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. <i>Lancet</i> , The, 2018, 392, 1519-1529.	13.7	1,179
7	Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> , 2006, 29, 1963-1972.	8.6	1,089
8	UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. <i>Lancet</i> , The, 1997, 350, 1288-1293.	13.7	704
9	Long-Term Follow-up after Tight Control of Blood Pressure in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2008, 359, 1565-1576.	27.0	674
10	Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2007, 357, 1716-1730.	27.0	651
11	Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2009, 361, 1736-1747.	27.0	608
12	Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events. <i>New England Journal of Medicine</i> , 2010, 362, 1477-1490.	27.0	588
13	Sulfonylurea Inadequacy: Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). <i>Diabetes Care</i> , 2002, 25, 330-336.	8.6	534
14	Rosiglitazone-Associated Fractures in Type 2 Diabetes. <i>Diabetes Care</i> , 2008, 31, 845-851.	8.6	498
15	Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , the, 2018, 6, 105-113.	11.4	451
16	Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events. <i>New England Journal of Medicine</i> , 2010, 362, 1463-1476.	27.0	430
17	Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials. <i>American Heart Journal</i> , 2006, 152, 27-38.	2.7	413
18	Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. <i>Lancet Diabetes and Endocrinology</i> , the, 2017, 5, 431-437.	11.4	379

#	ARTICLE	IF	CITATIONS
19	Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care™ Expert Forum. <i>Diabetes Care</i> , 2018, 41, 14-31.	8.6	338
20	The Lancet Commission on diabetes: using data to transform diabetes care and patient lives. <i>Lancet</i> , The, 2020, 396, 2019-2082.	13.7	327
21	Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. <i>Lancet Diabetes and Endocrinology</i> , the, 2014, 2, 843-851.	11.4	260
22	Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , the, 2017, 5, 877-886.	11.4	245
23	Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. <i>Lancet</i> , The, 2010, 375, 1365-1374.	13.7	228
24	Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus. <i>JAMA Cardiology</i> , 2016, 1, 126.	6.1	196
25	Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. <i>Lancet</i> , The, 2014, 383, 2008-2017.	13.7	194
26	Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin. <i>Nature Genetics</i> , 2016, 48, 1055-1059.	21.4	165
27	Framingham, SCORE, and DECODE Risk Equations Do Not Provide Reliable Cardiovascular Risk Estimates in Type 2 Diabetes. <i>Diabetes Care</i> , 2007, 30, 1292-1293.	8.6	158
28	Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , the, 2014, 2, 116-124.	11.4	157
29	Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS. <i>Diabetes Care</i> , 2016, 39, 2304-2310.	8.6	142
30	Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. <i>American Heart Journal</i> , 2013, 166, 983-989.e7.	2.7	116
31	Prognostic Significance of Silent Myocardial Infarction in Newly Diagnosed Type 2 Diabetes Mellitus. <i>Circulation</i> , 2013, 127, 980-987.	1.6	99
32	Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data. <i>Diabetes Care</i> , 2018, 41, 1844-1853.	8.6	91
33	Cardiometabolic multimorbidity is associated with a worse Covid-19 prognosis than individual cardiometabolic risk factors: a multicentre retrospective study (CoViDiab II). <i>Cardiovascular Diabetology</i> , 2020, 19, 164.	6.8	90
34	Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: Rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. <i>American Heart Journal</i> , 2008, 156, 623-632.	2.7	84
35	Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. <i>American Heart Journal</i> , 2016, 174, 103-110.	2.7	82
36	Aspects of Multicomponent Integrated Care Promote Sustained Improvement in Surrogate Clinical Outcomes: A Systematic Review and Meta-analysis. <i>Diabetes Care</i> , 2018, 41, 1312-1320.	8.6	81

#	ARTICLE	IF	CITATIONS
37	Real-world studies no substitute for RCTs in establishing efficacy. <i>Lancet</i> , The, 2019, 393, 210-211.	13.7	78
38	Hyperglycemia and hyperinsulinemia at diagnosis of diabetes and their association with subsequent cardiovascular disease in the United Kingdom Prospective Diabetes Study (UKPDS 47). <i>American Heart Journal</i> , 1999, 138, S353-S359.	2.7	77
39	Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy. <i>Diabetes Care</i> , 2018, 41, 705-712.	8.6	67
40	Renal Function in Type 2 Diabetes with Rosiglitazone, Metformin, and Glyburide Monotherapy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1032-1040.	4.5	64
41	Time trends in prescribing of type 2 diabetes drugs, glycaemic response and risk factors: A retrospective analysis of primary care data, 2010-2017. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1576-1584.	4.4	64
42	Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial. <i>Diabetes Care</i> , 2020, 43, 446-452.	8.6	63
43	Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus. <i>Circulation</i> , 2020, 141, 843-862.	1.6	62
44	Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial. <i>Diabetes Care</i> , 2017, 40, 1763-1770.	8.6	60
45	Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype. <i>Diabetes Care</i> , 2018, 41, 596-603.	8.6	59
46	Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes. <i>Circulation</i> , 2019, 140, 1613-1622.	1.6	58
47	Sitagliptin and risk of fractures in type 2 diabetes: results from the TECOS trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 78-86.	4.4	52
48	Historical HbA1c Values May Explain the Type 2 Diabetes Legacy Effect: UKPDS 88. <i>Diabetes Care</i> , 2021, 44, 2231-2237.	8.6	51
49	Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial. <i>American Heart Journal</i> , 2014, 168, 23-29.e2.	2.7	50
50	Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). <i>Diabetes Care</i> , 2017, 40, 494-501.	8.6	50
51	Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). <i>American Heart Journal</i> , 2017, 187, 1-9.	2.7	49
52	Pancreatic Safety of Sitagliptin in the TECOS Study. <i>Diabetes Care</i> , 2017, 40, 164-170.	8.6	49
53	Non-HDL Cholesterol Is Less Informative Than the Total-to-HDL Cholesterol Ratio in Predicting Cardiovascular Risk in Type 2 Diabetes. <i>Diabetes Care</i> , 2005, 28, 1796-1797.	8.6	48
54	Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial. <i>Cardiovascular Diabetology</i> , 2019, 18, 138.	6.8	48

#	ARTICLE	IF	CITATIONS
55	Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , 2017, 136, 1193-1203.	1.6	47
56	Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 356-363.	4.4	47
57	Effects of Intensive Blood Pressure Treatment on Orthostatic Hypotension. <i>Annals of Internal Medicine</i> , 2021, 174, 58-68.	3.9	47
58	Association of obesity with cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: Insights from TECOS. <i>American Heart Journal</i> , 2020, 219, 47-57.	2.7	45
59	A1C Targets Should Be Personalized to Maximize Benefits While Limiting Risks. <i>Diabetes Care</i> , 2018, 41, 1121-1124.	8.6	43
60	Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans. <i>Nature Communications</i> , 2020, 11, 3766.	12.8	43
61	Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001238.	2.8	43
62	Renal Outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL). <i>Diabetes</i> , 2018, 67, .	0.6	42
63	The UK Prospective Diabetes Study. <i>Annals of Medicine</i> , 1996, 28, 439-444.	3.8	39
64	Determining the most appropriate components for a composite clinical trial outcome. <i>American Heart Journal</i> , 2008, 156, 633-640.	2.7	38
65	Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL. <i>Diabetes Care</i> , 2020, 43, 643-652.	8.6	38
66	Time-varying risk of microvascular complications in latent autoimmune diabetes of adulthood compared with type 2 diabetes in adults: a post-hoc analysis of the UK Prospective Diabetes Study 30-year follow-up data (UKPDS 86). <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 206-215.	11.4	36
67	Understanding the outcomes of multi-centre clinical trials: A qualitative study of health professional experiences and views. <i>Social Science and Medicine</i> , 2012, 74, 574-581.	3.8	35
68	Optimal management of T2DM remains elusive. <i>Nature Reviews Endocrinology</i> , 2013, 9, 67-68.	9.6	34
69	A proteomic surrogate for cardiovascular outcomes that is sensitive to multiple mechanisms of change in risk. <i>Science Translational Medicine</i> , 2022, 14, eabj9625.	12.4	31
70	Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2379-2388.	4.4	29
71	Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study. <i>Diabetes Care</i> , 2020, 43, 2493-2499.	8.6	29
72	Metformin in non-diabetic hyperglycaemia: the GLINT feasibility RCT. <i>Health Technology Assessment</i> , 2018, 22, 1-64.	2.8	28

#	ARTICLE	IF	CITATIONS
73	Initiating Insulin as Part of the Treating To Target in Type 2 Diabetes (4-T) Trial: An interview study of patients' and health professionals' experiences. <i>Diabetes Care</i> , 2010, 33, 2178-2180.	8.6	27
74	Long-term risk of cardiovascular disease in individuals with latent autoimmune diabetes in adults (UKPDS 85). <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2115-2122.	4.4	27
75	Challenges of maintaining research protocol fidelity in a clinical care setting: A qualitative study of the experiences and views of patients and staff participating in a randomized controlled trial. <i>Trials</i> , 2011, 12, 108.	1.6	26
76	Effect of once-weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the EXSCEL trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2493-2498.	4.4	26
77	Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008018.	3.9	25
78	Increased Risk of Incident Heart Failure and Death Is Associated With Insulin Resistance in People With Newly Diagnosed Type 2 Diabetes: UKPDS 89. <i>Diabetes Care</i> , 2021, 44, 1877-1884.	8.6	25
79	Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine. <i>Diabetes Care</i> , 2022, 45, 204-212.	8.6	25
80	Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1587-1593.	4.4	24
81	Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial. <i>BMJ Open</i> , 2012, 2, e001925.	1.9	23
82	Effect of race on the glycaemic response to sitagliptin: Insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1427-1434.	4.4	23
83	Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL. <i>Diabetes Care</i> , 2019, 42, 318-326.	8.6	23
84	Temporal Validation of the UKPDS Outcomes Model Using 10-Year Posttrial Monitoring Data. <i>Diabetes Care</i> , 2013, 36, 1541-1546.	8.6	21
85	Î ² -cell secretory dysfunction: a key cause of type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 370.	11.4	21
86	Effect of Once-weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial. <i>Journal of the American Heart Association</i> , 2018, 7, e009304.	3.7	19
87	Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials. <i>Circulation</i> , 2019, 139, 863-873.	1.6	18
88	Association between glycated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the TECOS randomized clinical trial. <i>European Journal of Heart Failure</i> , 2020, 22, 2026-2034.	7.1	18
89	Design and rationale of the EMPA-VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure. <i>ESC Heart Failure</i> , 2021, 8, 2580-2590.	3.1	18
90	Meta-analysis of the impact of alpha-glucosidase inhibitors on incident diabetes and cardiovascular outcomes. <i>Cardiovascular Diabetology</i> , 2019, 18, 135.	6.8	17

#	ARTICLE	IF	CITATIONS
91	TriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes who have suboptimal glycaemic control on metformin treatment with or without a sulfonylureaâ€”a MASTERMIND study protocol. <i>BMJ Open</i> , 2020, 10, e042784.	1.9	17
92	Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL). <i>Diabetes Care</i> , 2019, 42, 1075-1080.	8.6	15
93	Accurately Reflecting Uncertainty When Using Patient-Level Simulation Models to Extrapolate Clinical Trial Data. <i>Medical Decision Making</i> , 2020, 40, 460-473.	2.4	15
94	Evaluation of a Self-Administered Oral Glucose Tolerance Test. <i>Diabetes Care</i> , 2013, 36, 1483-1488.	8.6	14
95	Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS. <i>Cardiovascular Diabetology</i> , 2019, 18, 116.	6.8	14
96	Long-term glucose variability and risk of nephropathy complication in UKPDS, ACCORD and VADT trials. <i>Diabetologia</i> , 2020, 63, 2482-2485.	6.3	14
97	The effect of glibenclamide on insulin secretion at normal glucose concentrations. <i>Diabetologia</i> , 2015, 58, 43-49.	6.3	13
98	Effects of Once-Weekly Exenatide on Clinical Outcomes in Patients With Preexisting Cardiovascular Disease. <i>Circulation</i> , 2018, 138, 2576-2578.	1.6	13
99	The effect of a brief action planning intervention on adherence to double-blind study medication, compared to a standard trial protocol, in the Atorvastatin in Factorial with Omega EE90 Risk Reduction in Diabetes (AFORRD) clinical trial: A cluster randomised sub-study. <i>Diabetes Research and Clinical Practice</i> , 2016, 120, 56-64.	2.8	12
100	Hypertension Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events. <i>Hypertension</i> , 2017, 70, 907-914.	2.7	12
101	Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 798-806.	4.4	11
102	Impact of Acarbose on Incident Diabetes and Regression to Normoglycemia in People With Coronary Heart Disease and Impaired Glucose Tolerance: Insights From the ACE Trial. <i>Diabetes Care</i> , 2020, 43, 2242-2247.	8.6	11
103	Baseline Characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial Population: Comparison with Other Diabetes Prevention Trials. <i>Cardiovascular Therapeutics</i> , 2010, 28, 124-132.	2.5	10
104	Estimating risk factor progression equations for the UKPDS Outcomes Model 2 (UKPDS 90). <i>Diabetic Medicine</i> , 2021, 38, e14656.	2.3	10
105	Validation of the WATCHâ€”DM and TRSâ€”HF _{DM} Risk Scores to Predict the Risk of Incident Hospitalization for Heart Failure Among Adults With Type 2 Diabetes: A Multicohort Analysis. <i>Journal of the American Heart Association</i> , 2022, 11, .	3.7	10
106	Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes. <i>Circulation</i> , 2020, 141, 1360-1370.	1.6	9
107	Predictors of Stroke in Patients With Impaired Glucose Tolerance. <i>Stroke</i> , 2013, 44, 2590-2593.	2.0	8
108	Can the cardiovascular risk reductions observed with empagliflozin in the EMPAâ€”REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1151-1156.	4.4	8

#	ARTICLE	IF	CITATIONS
109	An outcome model approach to transporting a randomized controlled trial results to a target population. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2019, 26, 429-437.	4.4	7
110	Progression of glucose-lowering diabetes therapy in TECOS. <i>Endocrinology, Diabetes and Metabolism</i> , 2019, 2, e00053.	2.4	7
111	Neck circumference and waist circumference associated with cardiovascular events in type 2 diabetes (Beijing Community Diabetes Study 23). <i>Scientific Reports</i> , 2021, 11, 9491.	3.3	7
112	Perceptions of heart attack risk amongst individuals with diabetes. <i>Primary Care Diabetes</i> , 2009, 3, 239-244.	1.8	6
113	Polyvascular disease and increased risk of cardiovascular events in patients with type 2 diabetes: Insights from the EXSCEL trial. <i>Atherosclerosis</i> , 2021, 338, 1-6.	0.8	6
114	Effect of Fenofibrate Therapy on Laser Treatment for Diabetic Retinopathy: A Meta-Analysis of Randomized Controlled Trials. <i>Diabetes Care</i> , 2022, 45, e1-e2.	8.6	6
115	A Novel Risk Classification Paradigm for Patients With Impaired Glucose Tolerance and High Cardiovascular Risk. <i>American Journal of Cardiology</i> , 2013, 112, 231-237.	1.6	5
116	Updated risk factors should be used to predict development of diabetes. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 859-863.	2.3	5
117	Longitudinal medical resources and costs among type 2 diabetes patients participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1732-1739.	4.4	5
118	Baseline characteristics and temporal differences in Acarbose Cardiovascular Evaluation (ACE) trial participants. <i>American Heart Journal</i> , 2018, 199, 170-175.	2.7	5
119	Improved Framingham Risk Scores of Patients with Type 2 Diabetes Mellitus in the Beijing Community: A 10-Year Prospective Study of the Effects of Multifactorial Interventions on Cardiovascular Risk Factors (The Beijing Communities Diabetes Study 22). <i>Diabetes Therapy</i> , 2020, 11, 885-903.	2.5	5
120	Predicting major adverse limb events in individuals with type 2 diabetes: Insights from the EXSCEL trial. <i>Diabetic Medicine</i> , 2021, 38, e14552.	2.3	5
121	Presenting the results of clinical trials to participants. <i>Clinical Medicine</i> , 2009, 9, 415-416.	1.9	4
122	Cardiovascular outcome trials of glucose-lowering strategies in type 2 diabetes—Authors' reply. <i>Lancet, The</i> , 2014, 384, 1097-1098.	13.7	4
123	International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	4
124	What does the Acarbose Cardiovascular Evaluation (ACE) trial tell us?. <i>Journal of Diabetes</i> , 2018, 10, 683-685.	1.8	4
125	Associations between β -blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease. <i>American Heart Journal</i> , 2019, 218, 92-99.	2.7	4
126	International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS. <i>American Heart Journal</i> , 2019, 218, 57-65.	2.7	4

#	ARTICLE	IF	CITATIONS
127	Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). <i>Diabetes Care</i> , 2020, 43, 374-381.	8.6	4
128	Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: Insights from the Acarbose Cardiovascular Evaluation (ACE) trial. <i>Diabetes Research and Clinical Practice</i> , 2020, 170, 108488.	2.8	4
129	Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: Observations from the <scp>EXSCEL</scp> and <scp>SAVORâ€TIMI</scp> 53 cardiovascular outcomes trials. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1101-1110.	4.4	4
130	Effect of once-weekly exenatide on hospitalization for acute coronary syndrome or coronary revascularization in patients with type 2 diabetes mellitus. <i>American Heart Journal</i> , 2021, 239, 59-63.	2.7	4
131	Health selection into neighborhoods among patients enrolled in a clinical trial. <i>Preventive Medicine Reports</i> , 2017, 8, 51-54.	1.8	3
132	Simulating the impact of targeting lower systolic blood pressure and LDL-cholesterol levels on type 2 diabetes complication rates. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 69-74.	2.3	3
133	Low-density lipoprotein cholesterol treatment and outcomes in patients with type 2 diabetes and established cardiovascular disease: Insights from TECOS. <i>American Heart Journal</i> , 2020, 220, 82-88.	2.7	3
134	Benchmarking the Cost-Effectiveness of Interventions Delaying Diabetes: A Simulation Study Based on NAVIGATOR Data. <i>Diabetes Care</i> , 2020, 43, 2485-2492.	8.6	3
135	Economic Evaluation of Factorial Trials: Cost-Utility Analysis of the Atorvastatin in Factorial With Omega EE90 Risk Reduction in Diabetes 2Â— 2Â— 2 Factorial Trial of Atorvastatin, Omega-3 Fish Oil, and Action Planning. <i>Value in Health</i> , 2020, 23, 1340-1348.	0.3	3
136	Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). <i>Cardiovascular Diabetology</i> , 2022, 21, .	6.8	3
137	Antithrombotic treatment gap among patients with atrial fibrillation and type 2 diabetes. <i>International Journal of Cardiology</i> , 2019, 289, 58-62.	1.7	2
138	Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on postâ€meal glucose excursions and glucagon in type 1 diabetes patients. <i>Endocrinology, Diabetes and Metabolism</i> , 2020, 3, e00130.	2.4	2
139	Predicting the risk of developing type 2 diabetes in Chinese people who have coronary heart disease and impaired glucose tolerance. <i>Journal of Diabetes</i> , 2021, 13, 817-826.	1.8	2
140	Lifetime cost-effectiveness simulation of once-weekly exenatide in type 2 diabetes: A cost-utility analysis based on the EXSCEL trial. <i>Diabetes Research and Clinical Practice</i> , 2022, 183, 109152.	2.8	2
141	Addition of exenatide to insulin therapy in individuals with type 2 diabetes in UK routine clinical practice. <i>Practical Diabetes</i> , 2012, 29, 61-64.	0.3	1
142	First-time heart failure increases risk of diabetes mellitus. <i>Nature Reviews Endocrinology</i> , 2014, 10, 453-454.	9.6	1
143	Clinically relevant results from cardiovascular outcome trials. <i>Nature Reviews Endocrinology</i> , 2018, 14, 67-68.	9.6	1
144	Comment on Kim et al. The Effect of a Smartphone-Based, Patient-Centered Diabetes Care System in Patients With Type 2 Diabetes: A Randomized, Controlled Trial for 24 Weeks. <i>Diabetes Care</i> 2019;42:3â€9. <i>Diabetes Care</i> , 2019, 42, e125-e125.	8.6	1

#	ARTICLE	IF	CITATIONS
145	Abstract MP36: Effects Of Intensive Blood Pressure Treatment On Orthostatic Hypotension: An Individual-level Meta-analysis. Hypertension, 2020, 76, .	2.7	1
146	Microvascular outcomes in type 2 diabetes â€“ Authors' reply. Lancet Diabetes and Endocrinology,the, 2017, 5, 580.	11.4	0
147	Comment on Davis et al. Effects of Severe Hypoglycemia on Cardiovascular Outcomes and Death in the Veterans Affairs Diabetes Trial. Diabetes Care 2019;42:157â€“163. Diabetes Care, 2019, 42, e95-e95.	8.6	0